Cynata Therapeutics Limited has executed a license option agreement with FUJIFILM Corporation of Japan for the development and commercialization of certain Cynata technology, including Cynata's lead induced pluripotent stem cell (iPSC)-derived therapeutic mesenchymal stem cell (MSC) product, CYP-001. The parties to collaborate on the further development and commercialization of Cynata's lead CymerusTM therapeutic MSC product CYP-001 for graft-versus-host disease (GvHD). Under this agreement, FUJIFILM has an option to an exclusive, worldwide licence to market and sell Cynata's lead MSC product, CYP-001, in the field of prevention and treatment of graft-versus-host disease (GvHD).